This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America

CSI: Cramer

When stocks are left for dead by the markets, Cramer's Stock Investigation, or CSI, unit is on the case, looking for clues as to what happened and whether there's anything investors can do about it. Tonight, he looked at the restaurant stocks of Red Robin Gourmet Burgers (RRGB) , Bloomin' Brands (BLMN) , Noodles & Company (NDLS) , Potbelly (PBPB) and Chuy's (CHUY) , all of which were victims of a market hit-and-run.

Cramer said all five of these stocks had one thing in common -- they were all much-hyped growth stories touted to be the next Chipotle Mexican Grill (CMG) . Unfortunately, when managements stumble, the value investors head for the exits in droves.

Red Robin shares doubled in 2013, but after growth stalled shares have plummeted 30% so far in 2014. Cramer called the chain's most recent quarter a huge disappointment and said investors need to stay far away.

Noodles & Company had a much-hyped IPO in June of last year but has been declining ever since, with the company posting a nasty earnings miss with declining same-store sales. Similar story with Potbelly, with that stock being cut to pieces and still having a outrageously high multiple, Cramer noted.

Must Read: Roche Investors Should Breathe Easier After InterMune Acquisition

Chuy's is also following the same pattern, said Cramer -- the company is focused on opening new stores while the existing ones are floundering through mismanagement.

Finally, there's Bloomin' Brands, purveyors of Outback Steakhouse and four other chains. Cramer said this stock is also down 32% this year. Its growth has stalled and management struggles to right the ship. He advised investors to steer clear of all of these stocks because their shares have not yet found a bottom.

Executive Decision: Mark Trudeau

In his second "Executive Decision" segment, Cramer sat down with Mark Trudeau, president and CEO of Mallinckrodt Pharmaceuticals (MNK - Get Report) , a fast-growing biotech located in the much-sought-after domicile of Ireland.

Trudeau explained that Mallinckrodt has always been an Irish company since its creation in 2009. While that affords the company some advantages, the focus continues to be on creating value to patients.

Trudeau continued that Mallinckrodt is always on the lookout for companies that offer a good strategic fit to what it is doing internally. He said the company's two most recent acquisitions -- Cadence and Questcor Pharmaceuticals -- were two such deals that will offer long-term benefits for patients and shareholders alike.

When asked about the controversy surrounding the acquisition of the drug Acthar, Trudeau explained that Acthar is available for 19 indications and is usually a drug of last resort when others have failed. So he's not worried, as some are, that insurance reimbursements may diminish over time.

Cramer said Mallinckrodt remains a well-run company with a terrific outlook for growth.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNK $69.48 0.00%
PLKI $60.02 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs